@article{VATS4751,
author = {Natalie Lui},
title = {Neoadjuvant chemotherapy versus chemoradiotherapy for esophageal cancer: a tradeoff between dysphagia and pathologic response},
journal = {Video-Assisted Thoracic Surgery},
volume = {3},
number = {0},
year = {2018},
keywords = {},
abstract = {Sunde et al. reported their findings on the relief of dysphagia after neoadjuvant chemoradiotherapy versus chemotherapy in patients with esophageal cancer (1). Dysphagia was a secondary endpoint in a multicenter, randomized clinical trial, NEOadjuvant therapy in RESectable esophageal cancer (NeoRes) (2,3). They found that patients who underwent neoadjuvant chemoradiotherapy had higher rates of dysphagia, but a better pathologic response, compared to patients who underwent neoadjuvant chemotherapy.},
issn = {2519-0792}, url = {https://vats.amegroups.org/article/view/4751}
}